Profound Medical appoints accomplished financial executive, Murielle Lortie, to board

Profound Medical

Profound Medical (NASDAQ:PROF; TSX:PRN) appointed financial executive, Murielle Lortie, as a director, effective immediately.

Ms. Lortie is the CFO of Liminal Biosciences, a Nasdaq-listed, clinical-stage biopharmaceutical company. She was previously VP, CFO and advisor to the CEO at Pharmascience; and held senior positions in finance at Bristol Myers Squibb.

In a statement, Arun Menawat, Ph.D., Profound’s CEO and chairman, said “I am very pleased to welcome [Ms. Lortie] to our team. She is not only an experienced executive in the life science industry, but also has a breadth of relevant public company and board experience that should be invaluable as Profound executes the next stages of its growth strategy.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.